A detailed history of Raymond James Financial Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 417,756 shares of ETNB stock, worth $6.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
417,756
Previous 571,602 26.91%
Holding current value
$6.2 Million
Previous $5.61 Million 9.25%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$8.02 - $14.96 $1.23 Million - $2.3 Million
-153,846 Reduced 26.91%
417,756 $6.13 Million
Q2 2025

Aug 14, 2025

BUY
$4.83 - $10.57 $914,372 - $2 Million
189,311 Added 49.52%
571,602 $5.61 Million
Q1 2025

May 13, 2025

BUY
$6.18 - $11.66 $30,411 - $57,378
4,921 Added 1.3%
382,291 $2.78 Million
Q4 2024

Feb 06, 2025

BUY
$7.03 - $10.05 $2.65 Million - $3.79 Million
377,370 New
377,370 $2.89 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $690M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Raymond James Financial Inc Portfolio

Follow Raymond James Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Inc with notifications on news.